Every major drug class of the last 50 years — statins, ACE inhibitors, PCR, CRISPR, GLP-1 agonists — traces back to a scientist who wasn't trying to cure anything at all.
The Peter Attia Drive
Every major drug class of the last 50 years — statins, ACE inhibitors, PCR, CRISPR, GLP-1 agonists — traces back to a scientist who wasn't trying to cure anything at all.
TL;DR
Peter Attia traces the hidden origins of six transformative drug classes — statins, ACE inhibitors, PCR, CRISPR, GFP, and GLP-1 agonists — back to curiosity-driven basic science involving jellyfish, fungi, snake venom, hot-spring microbes, salt-pond archaea, and a desert lizard [1] — Peter Attia "Every transformative drug class of the last 50 years traces back to a scientist studying something with no obvious medical relevance. Jelly…" 54:20 . None of the founding scientists were trying to cure disease; they were simply asking how nature works [2] — Peter Attia "If nature has already touched so many of these problems, then sometimes the most productive thing a scientist can do is not invent somethin…" 14:07 . The central argument: because evolution has been solving biological problems for 4 billion years, the organisms scientists study in the wild are often already sitting on the molecular solutions medicine needs [3] — Peter Attia "6 major drug classes from basic curiosity: Statins, ACE inhibitors, PCR, CRISPR, GFP, and GLP-1 agonists all trace back to curiosity-driven…" 54:30 . The single most actionable takeaway is that funding panels that demand near-term clinical relevance systematically filter out the research most likely to change everything.
Peter Attia traces the hidden origins of six transformative medical breakthroughs — GFP, statins, ACE inhibitors, PCR, CRISPR, and GLP-1 receptor agonists — back to curiosity-driven basic science involving jellyfish, fungi, snake venom, hot-spring microbes, salt-pond archaea, and a desert lizard, making the case for why funding basic research is essential to future medical innovation.
In the summer of 1961, Osamu Shimomura, his wife, and his mentor loaded into a station wagon and drove to Friday Harbor on San Juan Island to collect Aequorea victoria jellyfish. They cut the luminescent rings off the umbrellas by hand — one at a time — with scissors. Over 19 consecutive summers, they processed approximately 850,000 jellyfish. [1] — Peter Attia "850,000 jellyfish over 19 summers: Osamu Shimomura and his family cut the bells off approximately 850,000 jellyfish across 19 consecutive s…" 04:28 Shimomura's primary target was aequorin, a calcium-triggered blue-light-emitting protein, which he found. But lurking as a trace contaminant in every preparation was a second protein: one that did not glow on its own but emitted brilliant green light when excited by blue. He named it green fluorescent protein, or GFP, and published it. Almost nobody noticed for nearly 30 years. Then, in the early 1990s, biologists realized that GFP possessed three extraordinary properties no one had any reason to expect: it self-folds without helper machinery, self-assembles its fluorescent core from just three amino acids and oxygen, and — crucially — functions in virtually any organism on Earth. Because GFP is encoded by a single gene, you can attach that gene to any other gene you want, and the resulting protein will carry a green flashlight wherever it goes inside a living cell. [2] — Peter Attia "GFP ignored for nearly 30 years: After Shimomura discovered and published GFP, the protein sat largely ignored in the scientific literature…" 08:22 For the first time in history, scientists could watch biology happen in real time in living tissue: a cancer cell metastasizing through a mouse, neurons firing, an embryo developing cell by cell. Today, GFP or one of its engineered descendants is in use in virtually every major research lab on Earth. The 2008 Nobel Prize in Chemistry went to Shimomura, Martin Chalfie, and Roger Chen for work that began with a man and his family cutting jellyfish bells on a Washington State dock.
With the GFP story as his anchor, Peter broadens the argument. The reflexive way we talk about medical progress — 'we're working on a cure for Alzheimer's' — centers human intent and obscures a deeper truth: that an enormous amount of the most consequential progress has come not from people asking how to cure diseases, but from people asking how some piece of nature actually works. [1] — Peter Attia "Nature running experiments for ~4 billion years: Peter Attia emphasizes that evolution has been running experiments across millions of spec…" 12:50 Evolution is not optimizing for human longevity. It is not solving atherosclerosis or Alzheimer's. But it has, across roughly 4 billion years and millions of species, generated an almost unimaginably vast toolkit of molecules, signaling pathways, defense systems, and metabolic adaptations. The challenge, Peter argues, is recognizing nature's solutions when we encounter them — and having the cultural and funding infrastructure to support the scientists willing to go looking in places that don't at first seem medically relevant. The most productive thing a scientist can do, he proposes, is sometimes not to invent something new but to find the organism that already invented it.
By the late 1960s, the biochemistry of cholesterol synthesis was well understood, and every medicinal chemist in the field knew that inhibiting HMG-CoA reductase — the rate-limiting enzyme — should lower cholesterol. But nobody knew how to design such an inhibitor from scratch. Akira Endo at Sankyo in Tokyo took a different approach: instead of asking how to design an inhibitor, he asked who in nature had already designed one. [1] — Peter Attia "6,000+ microbial strains screened for statins: Akira Endo and Masao Kuroda screened more than 6,000 microbial strains over two years before…" 17:20 His reasoning was elegant. Fungi have been in chemical competition with bacteria for hundreds of millions of years. Many bacteria need sterols to build their cell membranes, so a fungus that could block bacterial sterol synthesis would have a lethal weapon. Penicillin was one such fungal weapon. An HMG-CoA reductase inhibitor could be another. Endo and his colleague Masao Kuroda screened over 6,000 microbial strains over two years before a strain of Penicillium citrinum from a Kyoto grain shop produced the hit they were looking for, in March 1972. Merck, working independently on a related compound from Aspergillus terreus, obtained FDA approval for lovastatin in 1987. [2] — Peter Attia "Lovastatin FDA approved 1987: Lovastatin, isolated by Merck from Aspergillus terreus and derived from Endo's original fungal finding, recei…" 18:10 From there came simvastatin, atorvastatin, rosuvastatin — the entire statin class that, by any reasonable estimate, has prevented millions of cardiovascular events and premature deaths. Peter notes that this is the cleanest example of a directed search for a natural solution: Endo had a hypothesis about where nature had already solved the problem, and he turned out to be right.
The story begins in Brazil in the 1940s, where pharmacologist Maurício Rocha e Silva was testing the hypothesis that pit viper venom caused circulatory shock by releasing histamine from blood plasma. The hypothesis was wrong. The venom released something else entirely: a potent vasodilating peptide he named bradykinin. A decade and a half later, Rocha e Silva's graduate student Sérgio Ferreira noticed that bradykinin in plasma was more active than synthetic bradykinin, and traced the discrepancy to a second family of venom peptides — Bradykinin Potentiating Factors (BPFs) — that protected bradykinin from degradation. [1] — Peter Attia "ACE inhibitor chain: 70 years of fieldwork: The entire ACE inhibitor drug class, from bradykinin's discovery in the 1940s to captopril's FD…" 26:30 Ferreira carried powdered BPF to London, to a lab studying pulmonary circulation, where postdoc Kevin Ng had discovered that angiotensin I converts to angiotensin II in the lungs. A key convergence: the same enzyme that destroyed bradykinin was also making angiotensin II — a dual-function regulator sitting at the center of the blood pressure system. Squibb's chemists used the smallest active BPF peptide as a structural lead and designed captopril, the first oral ACE inhibitor, approved by the FDA in 1981. [2] — Peter Attia "Captopril FDA approved 1981 — first oral ACE inhibitor: Captopril, designed using a venom peptide from Brazilian pit viper as its structura…" 25:00 From captopril came enalapril, lisinopril, ramipril, and ultimately the angiotensin receptor blockers. The renin-angiotensin-aldosterone system is now one of the most drugged pathways in medicine. The causal chain from a Brazilian snake farm to tens of millions of lives saved spans 70 years and five countries — and nobody in it set out to treat hypertension.
In the mid-1960s, Thomas Brock at Indiana University began spending summers in Yellowstone National Park, motivated by a simple question the microbiology community had largely dismissed: could anything live in near-boiling water? The prevailing view held that 55°C was roughly the biological ceiling. Brock disagreed and started looking. At Octopus Spring, he found pink filamentous bacteria growing at 80–88°C. [1] — Peter Attia "Taq polymerase survives 88°C+: Thermus aquaticus, discovered in Yellowstone hot springs, produces a DNA polymerase (Taq) that can survive t…" 32:20 Working with undergraduate Hudson Freeze, he isolated and cultured these thermophilic organisms — no small feat at their preferred temperature — and published a 1969 paper describing Thermus aquaticus, which he deposited in public culture collections. Nearly 15 years later, Kary Mullis at Cetus Corporation conceived PCR: denature DNA by heating near boiling, cool to allow primers to bind, extend with polymerase, repeat. Each cycle doubles the DNA; after 30 cycles, one molecule becomes a billion copies. The problem: the E. coli-derived polymerases of the time fell apart at the required temperatures, demanding fresh enzyme after every cycle — a tedious, expensive, error-prone process even with a purpose-built robot. The solution was Taq polymerase, already sitting in public collections since 1969. [2] — Peter Attia "30 PCR cycles = 1 molecule to 1 billion copies: After 30 cycles of PCR, a single DNA molecule is amplified into approximately one billion c…" 30:30 With Taq, PCR became automated, scalable, and cheap. Mullis won the Nobel Prize in Chemistry in 1993. But the technique's existence depends entirely on Brock and Freeze's decision, decades earlier, to look for life in boiling water — work that was funded and published without anyone asking what disease it would cure.
In the late 1980s, Francisco Mojica was doing his PhD at the University of Alicante, studying salt-tolerant archaea in the evaporative salt flats of Santa Pola on Spain's Mediterranean coast. His original project was scooped before publication, so he turned to a puzzling feature he kept noticing in the genome: clusters of short, regularly spaced palindromic repeats separated by unique spacer sequences. Nobody knew what they were. Mojica spent the entire 1990s and into the early 2000s trying to find out — with almost no institutional support and growing risk of being scooped. The breakthrough came in 2003 when he used the BLAST database to compare the spacer sequences against all sequenced genomes and found that they exactly matched DNA from bacteriophages — viruses that infect bacteria. [1] — Peter Attia "CRISPR paper rejected by 4 top journals: Francisco Mojica's landmark paper describing CRISPR as a bacterial adaptive immune system was reje…" 41:20 The spacers were memories. The repeats were the index of past infections. The organism had vaccinated itself against future phage attacks by storing fragments of the enemy's genome. This was an adaptive immune system in the simplest organisms in biology. Mojica's paper was rejected by Nature, PNAS, Molecular Microbiology, and Nucleic Acids Research before finally appearing in the Journal of Molecular Evolution in February 2005. From there the field accelerated rapidly: a 2007 Danisco paper validated CRISPR's immune function and identified Cas9; in 2012, Doudna, Charpentier, and Feng Zhang's group showed you could program the system with a custom guide RNA to cut DNA anywhere in any genome, and incorporate new sequences at the cut site. In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. [2] — Peter Attia "First CRISPR therapy FDA approved Dec 2023: In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy in clinical use, ind…" 44:10 Bacteria invented CRISPR 3 billion years ago. Mojica just noticed it.
In the late 1980s, clinical endocrinologist John Eng was seeing veterans with diabetes at the Bronx VA Medical Center and moonlighting in Rosalind Yalow's lab, which had developed uniquely sensitive peptide hormone assays using radioimmunoassay technology. Eng had read that Gila monster bites caused dramatic pancreatic inflammation in bitten animals, and he was struck by an additional fact: the Gila monster eats only 3 or 4 meals a year yet maintains stable blood glucose throughout long fasts — suggesting its pancreatic biology was doing something unusual. He ordered dried Gila monster venom and ran it through Yalow's assays. [1] — Peter Attia "Exendin-4 has 53% similarity to human GLP-1: Exendin-4, a peptide in Gila monster venom discovered by John Eng, showed 53% amino acid seque…" 48:58 Working with colleague Jean-Pierre Rothman, he systematically separated the peptide components, identified two peptides, and named the new one Exendin-4. When he sequenced it, the result was remarkable: 53% amino acid similarity to human GLP-1, the gut hormone that stimulates insulin secretion after meals. More importantly, while native GLP-1 has a half-life of only about 2 minutes — degraded almost instantly by the enzyme DPP-4 — Exendin-4 is resistant to DPP-4 and has a half-life measured in hours. Eng had discovered a long-acting GLP-1 receptor agonist hiding in lizard saliva. [2] — Peter Attia "Native GLP-1 half-life: ~2 minutes: Native human GLP-1 has a bloodstream half-life of only about 2 minutes due to rapid degradation by the …" 49:50 The VA declined to patent the discovery; Eng patented it himself and licensed it, eventually to Eli Lilly and Amylin. In 2005, the FDA approved synthetic Exendin-4 as Byetta (exenatide), the first GLP-1 receptor agonist. Subsequent drugs — liraglutide, semaglutide, tirzepatide — built on the biology, reducing immunogenicity and extending duration. The class is now reshaping the treatment of type 2 diabetes, obesity, and cardiovascular disease, with ongoing trials in heart failure, kidney disease, sleep apnea, addiction, and Alzheimer's disease.
With six case studies on the table, Peter makes the argument explicit. In every case but statins, the founding scientist was not trying to cure a disease — Shimomura was studying a jellyfish, Brock was studying extremophiles, Mojica was studying salt ponds, Eng was curious about pancreatic biology. If any of these projects had been submitted to a translational impact review panel — the kind that asks what disease will this cure and on what timeline — many would have struggled to survive. [1] — Peter Attia "I think we are systematically bad at predicting which curiosity-driven work is going to matter, but I'm not convinced there is actually a w…" 57:20 Some almost certainly would have been killed outright: 'I want to study how a jellyfish glows' is not a fundable proposal in that framework. And yet collectively, this body of work supports discoveries now improving or saving conservatively hundreds of millions of lives. There is almost nothing in modern medicine that doesn't, somewhere in its supply chain, depend on at least one of the discoveries described in this episode. Peter is careful about survivorship bias: he acknowledges that almost none of today's curiosity-driven projects will become GFP or CRISPR. But that, he argues, is precisely the point — we are extraordinarily bad at predicting in advance which ones will. [2] — Peter Attia "The criterion of near-term translational obvious impact, the criterion that asks of every project, what disease will this cure, is not alwa…" 58:10 The argument is not that all basic science deserves funding regardless of rigor. Peer review, accountability, and scientific merit still matter. The argument is more specific: applying near-term clinical relevance as the primary filter will systematically eliminate the very research most likely to produce the next paradigm shift. Directed science and basic science are not in competition; they are sequential stages of the same process. Curiosity-driven discovery has to come first because you cannot engineer around a mechanism you haven't found yet.
Chapter 1 · 02:30
In the summer of 1961, Osamu Shimomura, his wife, and his mentor loaded into a station wagon and drove to Friday Harbor on San Juan Island to collect Aequorea victoria jellyfish. They cut the luminescent rings off the umbrellas by hand — one at a time — with scissors. Over 19 consecutive summers, they processed approximately 850,000 jellyfish. [1] — Peter Attia "850,000 jellyfish over 19 summers: Osamu Shimomura and his family cut the bells off approximately 850,000 jellyfish across 19 consecutive s…" 04:28 Shimomura's primary target was aequorin, a calcium-triggered blue-light-emitting protein, which he found. But lurking as a trace contaminant in every preparation was a second protein: one that did not glow on its own but emitted brilliant green light when excited by blue. He named it green fluorescent protein, or GFP, and published it. Almost nobody noticed for nearly 30 years. Then, in the early 1990s, biologists realized that GFP possessed three extraordinary properties no one had any reason to expect: it self-folds without helper machinery, self-assembles its fluorescent core from just three amino acids and oxygen, and — crucially — functions in virtually any organism on Earth. Because GFP is encoded by a single gene, you can attach that gene to any other gene you want, and the resulting protein will carry a green flashlight wherever it goes inside a living cell. [2] — Peter Attia "GFP ignored for nearly 30 years: After Shimomura discovered and published GFP, the protein sat largely ignored in the scientific literature…" 08:22 For the first time in history, scientists could watch biology happen in real time in living tissue: a cancer cell metastasizing through a mouse, neurons firing, an embryo developing cell by cell. Today, GFP or one of its engineered descendants is in use in virtually every major research lab on Earth. The 2008 Nobel Prize in Chemistry went to Shimomura, Martin Chalfie, and Roger Chen for work that began with a man and his family cutting jellyfish bells on a Washington State dock.
Osamu Shimomura spent 19 summers cutting the bells off nearly a million jellyfish just to understand how they glow. The accidental byproduct — green fluorescent protein — became the single most widely used tool in modern biology, found in virtually every research lab on Earth.
Osamu Shimomura and his family cut the bells off approximately 850,000 jellyfish across 19 consecutive summers at Friday Harbor, Washington, leading to the discovery of GFP.
After Shimomura discovered and published GFP, the protein sat largely ignored in the scientific literature for almost 30 years before its revolutionary biological utility was recognized.
GFP has three properties nobody predicted from a random jellyfish protein: it folds itself, builds its own fluorescent core from just oxygen and three amino acids, and works in virtually any organism on Earth. That combination meant scientists could, for the first time, watch biology happen in real time inside living cells.
Chapter 2 · 10:45
With the GFP story as his anchor, Peter broadens the argument. The reflexive way we talk about medical progress — 'we're working on a cure for Alzheimer's' — centers human intent and obscures a deeper truth: that an enormous amount of the most consequential progress has come not from people asking how to cure diseases, but from people asking how some piece of nature actually works. [1] — Peter Attia "Nature running experiments for ~4 billion years: Peter Attia emphasizes that evolution has been running experiments across millions of spec…" 12:50 Evolution is not optimizing for human longevity. It is not solving atherosclerosis or Alzheimer's. But it has, across roughly 4 billion years and millions of species, generated an almost unimaginably vast toolkit of molecules, signaling pathways, defense systems, and metabolic adaptations. The challenge, Peter argues, is recognizing nature's solutions when we encounter them — and having the cultural and funding infrastructure to support the scientists willing to go looking in places that don't at first seem medically relevant. The most productive thing a scientist can do, he proposes, is sometimes not to invent something new but to find the organism that already invented it.
Evolution has run biochemical experiments across trillions of organisms for 4 billion years. Medicine doesn't need to invent solutions from scratch — it needs to recognize the solutions nature already built and engineer them into human therapies. That is the actual history of pharmacology.
Peter Attia emphasizes that evolution has been running experiments across millions of species for roughly 4 billion years, generating a vast toolkit of molecules and pathways medicine can exploit.
Fungi spend their existence in chemical warfare with bacteria, and one of their most effective weapons is blocking sterol synthesis. Akira Endo reasoned that if bacteria need sterols to live, some fungus had already evolved an HMG-CoA reductase inhibitor. He found it in a mold on rice in Kyoto.
Chapter 3 · 15:15
By the late 1960s, the biochemistry of cholesterol synthesis was well understood, and every medicinal chemist in the field knew that inhibiting HMG-CoA reductase — the rate-limiting enzyme — should lower cholesterol. But nobody knew how to design such an inhibitor from scratch. Akira Endo at Sankyo in Tokyo took a different approach: instead of asking how to design an inhibitor, he asked who in nature had already designed one. [1] — Peter Attia "6,000+ microbial strains screened for statins: Akira Endo and Masao Kuroda screened more than 6,000 microbial strains over two years before…" 17:20 His reasoning was elegant. Fungi have been in chemical competition with bacteria for hundreds of millions of years. Many bacteria need sterols to build their cell membranes, so a fungus that could block bacterial sterol synthesis would have a lethal weapon. Penicillin was one such fungal weapon. An HMG-CoA reductase inhibitor could be another. Endo and his colleague Masao Kuroda screened over 6,000 microbial strains over two years before a strain of Penicillium citrinum from a Kyoto grain shop produced the hit they were looking for, in March 1972. Merck, working independently on a related compound from Aspergillus terreus, obtained FDA approval for lovastatin in 1987. [2] — Peter Attia "Lovastatin FDA approved 1987: Lovastatin, isolated by Merck from Aspergillus terreus and derived from Endo's original fungal finding, recei…" 18:10 From there came simvastatin, atorvastatin, rosuvastatin — the entire statin class that, by any reasonable estimate, has prevented millions of cardiovascular events and premature deaths. Peter notes that this is the cleanest example of a directed search for a natural solution: Endo had a hypothesis about where nature had already solved the problem, and he turned out to be right.
Akira Endo and Masao Kuroda screened more than 6,000 microbial strains over two years before finding the first fungal inhibitor of HMG-CoA reductase that led to statins.
Lovastatin, isolated by Merck from Aspergillus terreus and derived from Endo's original fungal finding, received FDA approval in 1987 as the first commercial statin.
The causal chain from a Brazilian pit viper to captopril spans 70 years and five researchers across three continents, none of whom set out to develop a blood pressure drug. Each step answered only the question in front of it — and each answer unlocked the next.
Chapter 4 · 21:00
The story begins in Brazil in the 1940s, where pharmacologist Maurício Rocha e Silva was testing the hypothesis that pit viper venom caused circulatory shock by releasing histamine from blood plasma. The hypothesis was wrong. The venom released something else entirely: a potent vasodilating peptide he named bradykinin. A decade and a half later, Rocha e Silva's graduate student Sérgio Ferreira noticed that bradykinin in plasma was more active than synthetic bradykinin, and traced the discrepancy to a second family of venom peptides — Bradykinin Potentiating Factors (BPFs) — that protected bradykinin from degradation. [1] — Peter Attia "ACE inhibitor chain: 70 years of fieldwork: The entire ACE inhibitor drug class, from bradykinin's discovery in the 1940s to captopril's FD…" 26:30 Ferreira carried powdered BPF to London, to a lab studying pulmonary circulation, where postdoc Kevin Ng had discovered that angiotensin I converts to angiotensin II in the lungs. A key convergence: the same enzyme that destroyed bradykinin was also making angiotensin II — a dual-function regulator sitting at the center of the blood pressure system. Squibb's chemists used the smallest active BPF peptide as a structural lead and designed captopril, the first oral ACE inhibitor, approved by the FDA in 1981. [2] — Peter Attia "Captopril FDA approved 1981 — first oral ACE inhibitor: Captopril, designed using a venom peptide from Brazilian pit viper as its structura…" 25:00 From captopril came enalapril, lisinopril, ramipril, and ultimately the angiotensin receptor blockers. The renin-angiotensin-aldosterone system is now one of the most drugged pathways in medicine. The causal chain from a Brazilian snake farm to tens of millions of lives saved spans 70 years and five countries — and nobody in it set out to treat hypertension.
Maurício Rocha e Silva wasn't looking for bradykinin — he was testing a wrong hypothesis about histamine and circulatory shock. The accidental discovery of bradykinin, then of BPF, then of ACE's dual role in blood pressure, handed medicinal chemists a structural lead for captopril that no one had designed from first principles.
Captopril, designed using a venom peptide from Brazilian pit viper as its structural lead, was approved by the FDA in 1981 as the first oral ACE inhibitor in clinical use.
The entire ACE inhibitor drug class, from bradykinin's discovery in the 1940s to captopril's FDA approval in 1981, emerged from roughly 70 years of sequential curiosity-driven research without anyone initially intending to treat hypertension.
PCR was conceptually brilliant but practically useless until scientists needed a polymerase that could survive being heated to 95°C cycle after cycle. That enzyme had been sitting in public culture collections since 1969, isolated from a Yellowstone hot spring by a microbiologist who just wanted to know if life could exist at near-boiling temperatures.
Chapter 5 · 28:00
In the mid-1960s, Thomas Brock at Indiana University began spending summers in Yellowstone National Park, motivated by a simple question the microbiology community had largely dismissed: could anything live in near-boiling water? The prevailing view held that 55°C was roughly the biological ceiling. Brock disagreed and started looking. At Octopus Spring, he found pink filamentous bacteria growing at 80–88°C. [1] — Peter Attia "Taq polymerase survives 88°C+: Thermus aquaticus, discovered in Yellowstone hot springs, produces a DNA polymerase (Taq) that can survive t…" 32:20 Working with undergraduate Hudson Freeze, he isolated and cultured these thermophilic organisms — no small feat at their preferred temperature — and published a 1969 paper describing Thermus aquaticus, which he deposited in public culture collections. Nearly 15 years later, Kary Mullis at Cetus Corporation conceived PCR: denature DNA by heating near boiling, cool to allow primers to bind, extend with polymerase, repeat. Each cycle doubles the DNA; after 30 cycles, one molecule becomes a billion copies. The problem: the E. coli-derived polymerases of the time fell apart at the required temperatures, demanding fresh enzyme after every cycle — a tedious, expensive, error-prone process even with a purpose-built robot. The solution was Taq polymerase, already sitting in public collections since 1969. [2] — Peter Attia "30 PCR cycles = 1 molecule to 1 billion copies: After 30 cycles of PCR, a single DNA molecule is amplified into approximately one billion c…" 30:30 With Taq, PCR became automated, scalable, and cheap. Mullis won the Nobel Prize in Chemistry in 1993. But the technique's existence depends entirely on Brock and Freeze's decision, decades earlier, to look for life in boiling water — work that was funded and published without anyone asking what disease it would cure.
Kary Mullis conceived PCR but the technique was hobbled by heat-sensitive polymerases until Taq was available. With Taq, PCR became automated, scalable, and cheap — unlocking genetic testing, cancer diagnostics, forensics, vaccine development, and every gene therapy in existence.
After 30 cycles of PCR, a single DNA molecule is amplified into approximately one billion copies, enabling essentially all of modern molecular biology.
Thermus aquaticus, discovered in Yellowstone hot springs, produces a DNA polymerase (Taq) that can survive temperatures above 88°C, making automated PCR thermocycling possible.
Francisco Mojica spent the entire 1990s trying to understand a bizarre repeating pattern in salt pond archaea DNA. His eventual discovery — that bacteria have an adaptive immune system that remembers past virus infections — was rejected by four top journals before publication. That system is now CRISPR, and it just received FDA approval as a therapy for sickle cell disease.
Chapter 6 · 37:15
In the late 1980s, Francisco Mojica was doing his PhD at the University of Alicante, studying salt-tolerant archaea in the evaporative salt flats of Santa Pola on Spain's Mediterranean coast. His original project was scooped before publication, so he turned to a puzzling feature he kept noticing in the genome: clusters of short, regularly spaced palindromic repeats separated by unique spacer sequences. Nobody knew what they were. Mojica spent the entire 1990s and into the early 2000s trying to find out — with almost no institutional support and growing risk of being scooped. The breakthrough came in 2003 when he used the BLAST database to compare the spacer sequences against all sequenced genomes and found that they exactly matched DNA from bacteriophages — viruses that infect bacteria. [1] — Peter Attia "CRISPR paper rejected by 4 top journals: Francisco Mojica's landmark paper describing CRISPR as a bacterial adaptive immune system was reje…" 41:20 The spacers were memories. The repeats were the index of past infections. The organism had vaccinated itself against future phage attacks by storing fragments of the enemy's genome. This was an adaptive immune system in the simplest organisms in biology. Mojica's paper was rejected by Nature, PNAS, Molecular Microbiology, and Nucleic Acids Research before finally appearing in the Journal of Molecular Evolution in February 2005. From there the field accelerated rapidly: a 2007 Danisco paper validated CRISPR's immune function and identified Cas9; in 2012, Doudna, Charpentier, and Feng Zhang's group showed you could program the system with a custom guide RNA to cut DNA anywhere in any genome, and incorporate new sequences at the cut site. In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. [2] — Peter Attia "First CRISPR therapy FDA approved Dec 2023: In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy in clinical use, ind…" 44:10 Bacteria invented CRISPR 3 billion years ago. Mojica just noticed it.
Francisco Mojica's landmark paper describing CRISPR as a bacterial adaptive immune system was rejected by Nature, PNAS, Molecular Microbiology, and Nucleic Acids Research before finally being published in 2005.
In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy in clinical use, indicated for sickle cell disease.
John Eng at the Bronx VA Medical Center ordered dried Gila monster venom out of curiosity about pancreatic biology. He found Exendin-4, a peptide with 53% similarity to human GLP-1, a half-life of hours instead of minutes, and resistance to DPP-4 degradation. The result, eventually, was the entire GLP-1 receptor agonist drug class.
Chapter 7 · 47:30
In the late 1980s, clinical endocrinologist John Eng was seeing veterans with diabetes at the Bronx VA Medical Center and moonlighting in Rosalind Yalow's lab, which had developed uniquely sensitive peptide hormone assays using radioimmunoassay technology. Eng had read that Gila monster bites caused dramatic pancreatic inflammation in bitten animals, and he was struck by an additional fact: the Gila monster eats only 3 or 4 meals a year yet maintains stable blood glucose throughout long fasts — suggesting its pancreatic biology was doing something unusual. He ordered dried Gila monster venom and ran it through Yalow's assays. [1] — Peter Attia "Exendin-4 has 53% similarity to human GLP-1: Exendin-4, a peptide in Gila monster venom discovered by John Eng, showed 53% amino acid seque…" 48:58 Working with colleague Jean-Pierre Rothman, he systematically separated the peptide components, identified two peptides, and named the new one Exendin-4. When he sequenced it, the result was remarkable: 53% amino acid similarity to human GLP-1, the gut hormone that stimulates insulin secretion after meals. More importantly, while native GLP-1 has a half-life of only about 2 minutes — degraded almost instantly by the enzyme DPP-4 — Exendin-4 is resistant to DPP-4 and has a half-life measured in hours. Eng had discovered a long-acting GLP-1 receptor agonist hiding in lizard saliva. [2] — Peter Attia "Native GLP-1 half-life: ~2 minutes: Native human GLP-1 has a bloodstream half-life of only about 2 minutes due to rapid degradation by the …" 49:50 The VA declined to patent the discovery; Eng patented it himself and licensed it, eventually to Eli Lilly and Amylin. In 2005, the FDA approved synthetic Exendin-4 as Byetta (exenatide), the first GLP-1 receptor agonist. Subsequent drugs — liraglutide, semaglutide, tirzepatide — built on the biology, reducing immunogenicity and extending duration. The class is now reshaping the treatment of type 2 diabetes, obesity, and cardiovascular disease, with ongoing trials in heart failure, kidney disease, sleep apnea, addiction, and Alzheimer's disease.
The Gila monster eats only 3 or 4 meals per year yet maintains remarkably stable blood glucose levels throughout prolonged fasting, which drew John Eng's scientific attention.
Exendin-4, a peptide in Gila monster venom discovered by John Eng, showed 53% amino acid sequence similarity to human GLP-1, explaining its potent pancreatic effects.
Native human GLP-1 has a bloodstream half-life of only about 2 minutes due to rapid degradation by the DPP-4 enzyme, making it useless as a standalone drug.
Chapter 8 · 54:15
With six case studies on the table, Peter makes the argument explicit. In every case but statins, the founding scientist was not trying to cure a disease — Shimomura was studying a jellyfish, Brock was studying extremophiles, Mojica was studying salt ponds, Eng was curious about pancreatic biology. If any of these projects had been submitted to a translational impact review panel — the kind that asks what disease will this cure and on what timeline — many would have struggled to survive. [1] — Peter Attia "I think we are systematically bad at predicting which curiosity-driven work is going to matter, but I'm not convinced there is actually a w…" 57:20 Some almost certainly would have been killed outright: 'I want to study how a jellyfish glows' is not a fundable proposal in that framework. And yet collectively, this body of work supports discoveries now improving or saving conservatively hundreds of millions of lives. There is almost nothing in modern medicine that doesn't, somewhere in its supply chain, depend on at least one of the discoveries described in this episode. Peter is careful about survivorship bias: he acknowledges that almost none of today's curiosity-driven projects will become GFP or CRISPR. But that, he argues, is precisely the point — we are extraordinarily bad at predicting in advance which ones will. [2] — Peter Attia "The criterion of near-term translational obvious impact, the criterion that asks of every project, what disease will this cure, is not alwa…" 58:10 The argument is not that all basic science deserves funding regardless of rigor. Peer review, accountability, and scientific merit still matter. The argument is more specific: applying near-term clinical relevance as the primary filter will systematically eliminate the very research most likely to produce the next paradigm shift. Directed science and basic science are not in competition; they are sequential stages of the same process. Curiosity-driven discovery has to come first because you cannot engineer around a mechanism you haven't found yet.
Every transformative drug class of the last 50 years traces back to a scientist studying something with no obvious medical relevance. Jellyfish glow, fungal warfare, snake venom, hot springs, salt ponds, a desert lizard — the pattern is unmistakable once you see it.
Statins, ACE inhibitors, PCR, CRISPR, GFP, and GLP-1 agonists all trace back to curiosity-driven basic science with no original clinical intent.
The fundamental problem with demanding near-term translational relevance from every grant is that we are demonstrably terrible at predicting which curiosity-driven work will matter. This isn't an argument for funding all basic science — it's an argument against using 'what disease will this cure' as the primary filter.
Douglas Prasher, who cloned the GFP gene, could not secure NIH funding to continue his work, illustrating how the current funding framework actively disadvantages transformative basic science.
No indexed bits in this chapter.
Every transformative drug class of the last 50 years traces back to a scientist studying something with no obvious medical relevance. Jellyfish glow, fungal warfare, snake venom, hot springs, salt ponds, a desert lizard — the pattern is unmistakable once you see it.
Francisco Mojica spent the entire 1990s trying to understand a bizarre repeating pattern in salt pond archaea DNA. His eventual discovery — that bacteria have an adaptive immune system that remembers past virus infections — was rejected by four top journals before publication. That system is now CRISPR, and it just received FDA approval as a therapy for sickle cell disease.
This episode
Factual claims made this episode, and whether a source was named.
Osamu Shimomura and his team cut the bells off approximately 850,000 jellyfish drawn from a population of about 1 million over 19 consecutive summers at Friday Harbor, Washington.
GFP folds itself, builds its own fluorescent core from just three of its own amino acids using nothing but oxygen, and works in virtually any cell in any organism on Earth.
In 2008, the Nobel Prize in Chemistry was awarded to Osamu Shimomura, Martin Chalfie, and Roger Chen for the discovery and development of green fluorescent protein.
Konrad Bloch and Fyodor Leinen won the Nobel Prize for working out the basic biochemistry of cholesterol synthesis in 1964.
Akira Endo and Masao Kuroda screened more than 6,000 microbial strains over two years before finding the first fungal inhibitor of HMG-CoA reductase in Penicillium citrinum in March 1972.
Merck isolated lovastatin from Aspergillus terreus and received FDA approval for it in 1987, making it the first approved statin.
Captopril was approved by the FDA in 1981 as the first oral ACE inhibitor in clinical use.
After 30 cycles of PCR, a single DNA molecule is amplified into approximately one billion copies.
Thomas Brock observed pink filamentous bacteria growing in water at 80–88°C at Octopus Spring in Yellowstone, and published a paper characterizing Thermus aquaticus from Mushroom Spring in 1969.
Kary Mullis won the Nobel Prize in Chemistry in 1993 for inventing PCR.
Francisco Mojica's CRISPR paper was rejected by Nature, PNAS, Molecular Microbiology, and Nucleic Acids Research before being published by the Journal of Molecular Evolution in February 2005.
Danisco's 2007 paper in Science provided direct experimental evidence that CRISPR functions as an adaptive immune system in bacteria and identified Cas9 as the protein that recognizes CRISPR sequences to cut bacteriophage DNA.
Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for developing programmable CRISPR-Cas9 gene editing.
In December 2023, the FDA approved Casgevy, the first CRISPR-based therapy, for treatment of sickle cell disease.
Exendin-4 from Gila monster venom shows approximately 53% amino acid sequence similarity to human GLP-1.
Native human GLP-1 has a bloodstream half-life of approximately 2 minutes due to rapid degradation by the enzyme DPP-4.
Byetta (exenatide), the first GLP-1 receptor agonist, received FDA approval in 2005 for treatment of type 2 diabetes.
Douglas Prasher, who cloned the GFP gene, could not secure NIH funding to continue his work on GFP.
This episode
Japanese biochemist who discovered GFP after 19 summers studying bioluminescent jellyfish at Friday Harbor, Washington; awarded the 2008 Nobel Prize in Chemistry.
Spanish microbiologist at the University of Alicante whose decade-long investigation of repeating genomic sequences in salt pond archaea led to the identification of CRISPR.
Japanese biochemist at Sankyo Drug Company who screened over 6,000 fungal strains to find the first HMG-CoA reductase inhibitor, leading to the statin drug class.
Clinical endocrinologist at the Bronx VA Medical Center who discovered Exendin-4 in Gila monster venom, providing the foundation for the GLP-1 receptor agonist drug class.
Microbiologist at Indiana University who discovered Thermus aquaticus in Yellowstone hot springs, providing the Taq polymerase that made practical PCR possible.
Co-developer with Emmanuelle Charpentier of the programmable CRISPR-Cas9 gene editing system; awarded the 2020 Nobel Prize in Chemistry.
Biochemist at Cetus Corporation who conceived PCR; awarded the Nobel Prize in Chemistry in 1993.
Co-developer with Jennifer Doudna of programmable CRISPR-Cas9 gene editing; co-recipient of the 2020 Nobel Prize in Chemistry.
Pharmaceutical company that independently found lovastatin from Aspergillus terreus based on Endo's research and obtained the first statin FDA approval in 1987.
Pharmaceutical company that developed liraglutide and semaglutide, building on the GLP-1 receptor agonist class pioneered by Exendin-4.
Protein isolated from Aequorea victoria jellyfish by Shimomura; now a universal cell biology tool found in virtually every major research lab in the world.
Bacterial adaptive immune system discovered in salt pond archaea, repurposed as a programmable gene-editing tool; first therapeutic application approved by FDA in December 2023.
Thermophilic bacterium discovered by Thomas Brock in Yellowstone's hot springs; source of Taq polymerase, which made automated PCR thermocycling possible.
Venomous desert lizard native to the American Southwest whose venom contains Exendin-4, the structural basis for the GLP-1 receptor agonist drug class.
Brazilian lancehead pit viper whose venom, through sequential research, led to the discovery of bradykinin, ACE, and ultimately the ACE inhibitor drug class.
First oral ACE inhibitor, designed by Squibb chemists using a bradykinin potentiating factor from pit viper venom as structural lead; FDA approved 1981.
Bioluminescent jellyfish species native to the Pacific Northwest from which Osamu Shimomura isolated GFP, the foundational tool of modern cell biology.
The first CRISPR-based therapy approved by the FDA (December 2023) for the treatment of sickle cell disease.
GLP-1 receptor agonist developed by Novo Nordisk for type 2 diabetes and obesity; a descendant of the Exendin-4 discovery from Gila monster venom.
Site of Thomas Brock's discovery of Thermus aquaticus in near-boiling hot springs, providing the heat-stable Taq polymerase used in PCR.
Stats
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.